by Tony Chicotel, CANHR Staff Attorney
The Wall St. Journal is reporting that the U.S. Attorney’s Office is seeking a settlement of around $1 billion to resolve its investigation of illegal marketing tactics by Johnson & Johnson for its antipsychotic drug Risperdal. The settlement would follow a similar $1.4 billion settlement with pharma-giant Eli Lilly regarding the illegal marketing of Zyprexa as a treatment for dementia in 2009.
The specific allegations against Johnson & Johnson are not known but it is likely they include the promotion of “off-label” Risperdal use, such as for the elderly with dementia. The settlement is believed to be unrelated to an alleged multi-million dollar kickback scheme between Johnson & Johnson and Omnicare, the nation’s largest dispenser of prescription drugs in nursing homes.